2Kinzler KW, Vogelstein B. Landscaping the cancer terrain. Science, 1998, 280: 1036～1037.
3Krishnan K, Brenner DE. Chemoprevention of colorectal cancer. Gastroenterol ClinNorth Am,1996, 25: 821～858.
4Winawer SJ, Zauber AG, Gerdes H, O'Brien MJ,Gottlieb LS, Sternberg SS, Bond JH,Waye JD,Schapiro M, Panish JF, et al. Risk of colorectal cancer in the families ofpatients with adenomatous polyps. National Polyp Study Workgroup. N Engl J Med, 1996, 334:82～87.
5Sporn MB, Lippman SM. Chemoprevention of cancer. In: Holland JF, Bast RC Jr, MortonDL,Frei E III, Kufe DW, Weichselbaum RR, eds.Cancer Medicine. 4th, ed. Williams andWilkins,1997. 495～508.
6Brenner DE. Cancer chemoprevention. Curr Op Gastroenterol, 1999, 15: 9～15.
7Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol, 1983,24: 83～87.
8Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, Booker SV,Robinson CR, Offerhaus GJ. Treatment of colonic and rectal adenomas with sulindac infamilial adenomatous polyposis. N Engl J Med, 1993, 328: 1313～1316.
9Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirinuse and the risk for colorectal cancer and adenoma in male health professionals. AnnIntern Med, 1994, 121:241～246.
10Greenberg ER, Baron JA, Freeman DH Jr, Mandel JS, Haile R. Reduced risk oflarge-bowel adenomas among aspirin users. The Polyp Prevention Study Group. J Natl CancerInst, 1993, 85: 912～916.
